LENZ Therapeutics Inc (NASDAQ: LENZ) on Friday, plunged -7.48% from the previous trading day, before settling in for the closing price of $40.91. Within the past 52 weeks, LENZ’s price has moved between $16.53 and $41.22.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -181.63% annually for the last half of the decade. The company achieved an average annual earnings per share of -11.08%. With a float of $23.59 million, this company’s outstanding shares have now reached $28.50 million.
In an organization with 42 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 98.44%, operating margin of -1223.02%, and the pretax margin is -1024.42%.
LENZ Therapeutics Inc (LENZ) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of LENZ Therapeutics Inc is 16.72%, while institutional ownership is 92.20%. The most recent insider transaction that took place on Jul 10 ’25, was worth 6,506,784. In this transaction 10% Owner of this company sold 191,376 shares at a rate of $34.00, taking the stock ownership to the 1,575,899 shares. Before that another transaction happened on Jun 27 ’25, when Company’s 10% Owner sold 200,000 for $30.46, making the entire transaction worth $6,093,000. This insider now owns 1,767,275 shares in total.
LENZ Therapeutics Inc (LENZ) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.38 earnings per share (EPS) for the period topping the consensus outlook (set at -0.43) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 50.04% during the next five years compared to -181.63% drop over the previous five years of trading.
LENZ Therapeutics Inc (NASDAQ: LENZ) Trading Performance Indicators
LENZ Therapeutics Inc (LENZ) is currently performing well based on its current performance indicators. A quick ratio of 20.54 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 215.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.90, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.54 in one year’s time.
Technical Analysis of LENZ Therapeutics Inc (LENZ)
Let’s dig in a bit further. During the last 5-days, its volume was 1.24 million. That was better than the volume of 0.29 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 85.00%.
During the past 100 days, LENZ Therapeutics Inc’s (LENZ) raw stochastic average was set at 84.70%, which indicates a significant increase from 72.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.90 in the past 14 days, which was higher than the 2.15 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $32.11, while its 200-day Moving Average is $28.68. However, in the short run, LENZ Therapeutics Inc’s stock first resistance to watch stands at $40.47. Second resistance stands at $43.08. The third major resistance level sits at $44.47. If the price goes on to break the first support level at $36.47, it is likely to go to the next support level at $35.08. Assuming the price breaks the second support level, the third support level stands at $32.47.
LENZ Therapeutics Inc (NASDAQ: LENZ) Key Stats
Market capitalization of the company is 1.08 billion based on 28,522K outstanding shares. Right now, sales total 0 K and income totals -49,770 K. The company made 5,000 K in profit during its latest quarter, and -14,910 K in sales during its previous quarter.
